Latest filing published 11 Jan 2024 for Amylyx Pharmaceuticals, Inc., €42k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Patrick D. Yeramian: trading record in brief
Patrick D. Yeramian, listed as senior executive, appears in our data through filings on Amylyx Pharmaceuticals, Inc. shares, published by SEC (Form 4). Between 6 January 2022 and 9 January 2024, the trades on record add up to 20 filings.
No open-market purchase appears, only 10 sales worth €5.1M. Besides market trades, the filings include 3 share grants and 7 option exercises. So far in 2024, the count stands at no purchases and 1 sale.
The record was last updated on 11 January 2024 with an open-market sale (€42k) in Amylyx Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Patrick D. Yeramian
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,812 shares@ US$16.32812.5% of flowCommon StockSEC:0000950170-24-003974:0
- 2,201 shares@ US$0.370.0% of flowCommon StockSEC:0000950170-23-022775:0
- 44,861 shares@ US$0.370.9% of flowCommon StockSEC:0000899243-23-011461:0
- 2,789 shares@ US$0.330.1% of flowCommon StockSEC:0000899243-23-009600:0
- 52,211 shares@ US$31.848592.4% of flowCommon StockSEC:0000899243-23-009178:0
- 1,405 shares@ US$36.07892.8% of flowCommon StockSEC:0000899243-23-001526:0
- 629 shares@ US$36.78881.3% of flowCommon StockSEC:0000899243-23-001526:1
- 28,333 shares0Common StockSEC:0000899243-22-001522:0
8 of 8 declarations
